ETLI.F Legal & General UCITS ETF Plc - L&G Pharma Breakthrough UCITS ETF

ETF Healthcare Equity LGIM Managers (Europe) Limited Frankfurt Exchange
- EUR
No recent price
Total assets
36.5M
Expense ratio
0.50%
Dividend yield
0.92%
1-year return
+25.48%
Holdings
10
Since
2018

Fund data as reported by the issuer, updated Nov 11, 2026. Total assets are in the fund's base currency.

What does ETLI.F invest in?

Tracks Morningstar Gbl Biotechnology NR USD
  • Mostly US stocks (74.4%)
  • Largest sector: Healthcare (94.8%)
  • Largest region: North America (69.1%)
  • Top 3 holdings: 10.4% of the fund

Asset allocation

  • US stocks 74.4%
  • Non-US stocks 28.4%
  • Cash 0.2%

Top holdings

  • Genmab A/S 4.41%
  • Xeris Pharmaceuticals Inc 3.07%
  • United Therapeutics Corporation 2.92%
  • Ligand Pharmaceuticals Incorporated 2.86%
  • Xencor Inc 2.85%
All holdings, sectors and regions

Legal & General UCITS ETF Plc - L&G Pharma Breakthrough UCITS ETF performance

Sharpe ratio 0.60
This year
+1.17%
1 year
+25.48%
3 years
+3.47%
5 years
+1.30%

Volatility 16.0% over 1 year and 15.2% over 3 years. Moderate, similar to a broad stock index.

Total returns in the fund's currency as reported by the issuer; past returns do not predict future returns. Volatility is the yearly standard deviation of returns. Ask AI to explain these numbers

ETLI.F price

Prices on the chart can differ slightly from the closing prices StockSummer shows.